The Bcr/Abl fusion protein directly causes chronic myelogenous leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Multiple independent studies have implicated Crkl, a small adapter protein, in transduction of oncogenic signals of Bcr/Abl and Crkl tyrosine-phosphorylation is used as a diagnostic tool for Philadelphia-positive leukemia. To evaluate the contribution of Crkl to this type of leukemia, we generated mutant mice that lack Crkl expression. We found that the overall survival of P190 BCR/ABL crkl7/7 mice was comparable to that of genetically matched P190 BCR/ABL crkl +/+ mice. Both genotypes developed lymphoid lineage leukemia/lymphoma. Western blot analysis of 7/7 and +/+ lymphomas showed that the related Crk protein was tyrosine phosphorylated and could be found complexed with Bcr ± Abl P190. These data indicate that possible therapeutic approaches that target Crkl may be complicated by the presence of pathways that compensate for lack of Crkl function.
Introduction
The Bcr/Abl fusion protein is the product of the Philadelphia (Ph) chromosome, itself the result of a reciprocal translocation between chromosomes 22 and 9. The fusion of Bcr with the Abl tyrosine kinase in progenitor hematopoietic cells is responsible for the development of Ph-positive leukemia in man. The two forms of Bcr/Abl, P210 and P190, are predominantly associated with chronic myelogenous leukemia and Ph-positive acute lymphoblastic leukemia (ALL) (Sawyers, 1999; Deininger et al., 2000) . The Abl tyrosine kinase activity in P190 and P210 Bcr/Abl is deregulated and aberrantly tyrosine phosphorylates cellular substrates. Although a large number of such targets have been identi®ed, their signi®cance to the oncogenic process has not been clearly de®ned.
The adapter protein Crkl is one of the most prominent tyrosine phosphorylated Bcr/Abl substrates found in involved tissues of Ph-positive leukemic patients (Nichols et al., 1994; ten Hoeve et al., 1994a; Oda et al., 1994) . Small adapter proteins lack catalytic domains. Instead, they consist solely of SH2 and/or SH3 domains and function as linkers between other signaling proteins. Crkl consists of an amino-terminal SH2 domain, followed by two SH3 domains. The Nterminal SH3 domain of Crkl can form a constitutive complex with a number of proteins containing speci®c polyproline-rich regions, including C3G, an exchange factor for Rap1, and also Abl and Bcr/Abl. The SH2 domain of Crkl can interact with speci®c phosphorylated tyrosine residues in proteins such as Cas/Hef1 and Cbl. Crkl itself, as well as Cas/Hef1 and Cbl are substrates for the deregulated Bcr/Abl tyrosine kinase (reviewed by Sattler and Salgia, 1998; Feller et al., 1998; .
Dierent experimental approaches have provided evidence that Crkl plays an important role in transducing oncogenic signals of Bcr/Abl (ten Hoeve et al., 1994b; de Jong et al., 1995; Senechal et al., 1996; Heaney et al., 1997; Tari et al., 1997; Kolibaba et al., 1999; Kardinal et al., 2000; Hemmeryckx et al., 2001) . The correlation between the consistent and abnormal tyrosine phosphorylation of Crkl and Bcr/ Abl extends itself to transgenic mouse models for Phpositive ALL (de Jong et al., 1995) . Also, ablation of Crkl protein levels or blocking Crkl SH3-domain interactions were found to be growth-inhibitory for Bcr/Abl-expressing cells (Tari et al., 1997; . Recently, we have generated transgenic mice that signi®cantly overexpress Crkl protein in many cell types, including hematopoietic cells. The introduction of this transgene into a second line of transgenic mice that express Bcr/Abl P190 and reproducibly develop pre-B leukemia/lymphoma resulted in a marked acceleration of the development of this disease (Hemmeryckx et al., 2001) .
These results all imply that Crkl is important in signal transduction involving Bcr/Abl but do not directly address the question whether this small adapter protein is absolutely required for the generation of leukemia by the oncoprotein. Therefore, we have initiated experiments to generate crkl null mutant mice and have introduced the BCR/ABL P190 transgene into a crkl7/7 background. The analysis of leukemia/ lymphoma development in a matched cohort of P190 crkl7/7 and P190 crkl+/+ mice demonstrates that Crkl is dispensable for the development of Bcr/Ablassociated malignancy in transgenic mice. However, other proteins such as the related Crk could functionally compensate for the lack of Crkl.
Results

Leukemia/lymphoma develops in P190 BCR/ABL transgenics in the absence of Crkl
We generated mutants that were null for crkl by replacement of part of exon 1 of the murine crkl gene by the neomycin resistance gene. On the mixed genetic background used in these studies (129X1/SvJ6129S1/ Sv7+
/+6Black Swiss), crkl null mutants are viable and fertile (see Materials and methods).
To obtain a suitable cohort of animals for comparative studies, we mated P190 BCR/ABL double' transgenic females to crkl7/7 males. The ensuing progeny (P190 BCR/ABL transgenic, crkl+/ 7) was then intercrossed to obtain matched crkl7/7 and crkl+/+ P190 BCR/ABL genotypes. Previous experiments (Voncken et al., 1998) have shown that the speed with which leukemia develops in the P190 BCR/ ABL transgenic mice is markedly in¯uenced by the genetic background in which the transgene is expressed. Hence, we only used the F 1 generation of the P190 BCR/ABL transgenic, crkl+/7 intercrosses for this study. These animals were followed for the development of leukemia/lymphoma. As shown in Figure 1 , both genotypes succumbed to leukemia/ lymphoma, and on average, the crkl+/+ mice survived 200 days whereas the crkl7/7 mice survived only 158 days. However, analysis using the Log ± Rank test showed that this dierence did not attain statistical signi®cance.
Animals that were moribund were subjected to autopsies to compare the type of leukemia that developed. FACS analysis of the bone marrow of a leukemic crkl7/7 P190 BCR/ABL mouse and a wildtype P190 BCR/ABL animal showed that both developed B-lineage leukemia/lymphoma (Figure 2 ). All but one of the 7/7 and +/+ animals developed lymphoid leukemia (also see Materials and methods). As exempli®ed by PC 294 (a crkl+/+P190 BCR/ABL mouse), the leukemia was highly malignant, with pre-B lymphoblasts typically invading tissues such as sternum, lungs and lymph nodes (Figure 3a,d,g ) as well as spleen and liver (not shown). Identical targets were in®ltrated by pre-B blasts in a crkl7/7 P190 BCR/ ABL mouse PC 366 (Figure 3b ,e,h). Animal PC 158, also a crkl7/7 animal, developed myeloid lineage leukemia (Figure 3c ,f,i). Myeloid lineage leukemia was also previously found in P190 wild-type mice (Heisterkamp et al., 1990) . These results indicate that neither the type of leukemia (lymphoid versus myeloid) nor the overall survival is signi®cantly altered in the absence of Crkl and demonstrated that lack of Crkl still allows transduction of leukemogenic signals of Bcr/Abl P190 in transgenic mice.
Crk is involved in leukemia caused by P190 in transgenic mice
The crkl mutant generated by us clearly lacks production of any Crkl protein ( Figure 4a ). Thus, in view of the many signal transduction processes in hematopoietic cells that involve Crkl, it was surprising that the null mutant is fully viable and fertile in a mixed genetic background. This suggests that other protein(s) are functionally compensating for the lack of Crkl. Crk is the only other protein in mouse and man that is highly related to Crkl (ten Hoeve et al., 1993) . We therefore considered the possibility that Crk could functionally compensate for the lack of Crkl in leukemia/lymphoma development in the P190 BCR/ ABL transgenic mice.
We compared Crk protein levels in the spleens, peripheral blood leukocytes, hepatocytes, muscle, kidney and heart of 7/7 and sibling +/+ mice but no dierences were found (not shown). We also examined expression levels of Crk in the P190 lymphomas. The crk gene encodes two products, a larger Crk II protein that includes the SH2 and both SH3 domains, as well as a smaller form, Crk I, that lacks the C-terminal SH3 domain (Matsuda et al., 1992) and both were present in the P190 lymphomas ( Figure 4a ). However, as shown in Figure 4a , ablation of Crkl did not increase expression levels of Crk I or Crk II in these or three other lymphoma samples.
Tyrosine phosphorylation of Crkl is a hallmark of Ph-positive leukemia, is normally not found in nonstimulated hematopoietic cells, and has even been used as a diagnostic marker for Bcr/Abl activity (Nichols et al., 1994; ten Hoeve et al., 1994a; Oda et al., 1994; Gorre et al., 2001) . The phosphorylation of Crk and Crkl is detectable as a small upward shift in mobility (Reichman et al., 1992; Senechal et al., 1996; de Jong et al., 1997) . To investigate if Crk is phosphorylated in P190 Bcr/Abl-generated lymphomas we analysed dierent lymphoma samples from both crkl7/7 and +/+ animals. As shown in Figure 4b , phosphorylated Crk could be detected in the samples. The levels of phosphorylated Crk varied, with some samples showing a relatively high amount of Crk II-P (lanes 1 and 3), whereas other samples had very low levels (lane 5). This sample-to-sample variation in the ratio of phosphorylated to non-phosphorylated Crk is similar to that found for Crkl in comparable samples (not shown).
To extend these observations, we also immunoprecipitated Crkl and Crk II from a wild-type and a crkl7/7 lymphoma lysate and compared their levels of tyrosine phosphorylation (Figure 4c ). This showed, in agreement with previous results (de Jong et al., 1995) , that considerably more Crkl than Crk II is tyrosine phosphorylated in the crkl+/+ leukemic cells and con®rmed that the level of tyrosine phosphorylated Crk II, although clearly detectable, was not greatly enhanced by the absence of Crkl.
We also examined immunoprecipitates of Crk for the presence of Abl and Bcr/Abl using anti-Abl antibodies (Figure 4d ). We were able to detect co-precipitation of Abl and Bcr/Abl P190 with Crk II in lymphoma samples of P190 crkl+/+mice (Figure 4d ). Also, we could detect Bcr/Abl and Abl in Crk II immunoprecipitates of 7/7 mice ( Figure 4d , 7/7 sample).
Discussion
The crkl null mutation described in this study gives a Oncogene Ablation of Crkl in Bcr/Abl-associated leukemia B Hemmeryckx et al obtain live-born progeny (unpublished results). Similarly, Guris et al. (2001) reported that the null mutant they generated, which was in a mixed (129S4/ SvJaeSor6C57BI/6J) background, was essentially embryonic lethal. Thus, the severity of the phenotype of the null mutation appears to be strongly dependent upon genetic background.
Crkl is widely expressed during embryonic development and is involved in important cytokine and adhesion signaling processes. The ®nding that the crkl null mutation gives a viable phenotype in an outbred genetic background indicates that functional redundancy exists, that compensates for lack of Crkl in this background. The related Crk II protein, of which the expression pattern overlaps with that of Crkl, is the most obvious candidate for this function. However, we did not ®nd dierences in expression levels of Crk II in the spleen and peripheral blood lymphocytes of 129X1/SvJ and 129X1/SvJ6129S1/ Sv7+ p + Tyr7c Kitl SI7J /+6Black Swiss mice (not shown). This suggests that other genetic modi®ers determine the severity of the crkl null mutant phenotype.
A large number of studies, including our own, provided direct or indirect evidence that Crkl is important in signal transduction pathways that originate from the Bcr/Abl oncoprotein. We found that in transgenic mice overexpressing signi®cant amounts of Crkl protein, leukemia development by P190 BCR/ ABL was accelerated, which suggested that Crkl levels are rate-limiting for leukemogenesis (Hemmeryckx et al., 2001 ). In the current study, we have shown that in P190 BCR/ABL transgenic mice, Crkl is not needed for leukemia/lymphoma development. It is possible that these dierent eects are related to the genetic background in which these studies were performed, since the crkl null mutant6P190 transgenic study was in a (129X1/SvJ6129S1/Sv7+ p + Tyr7c Kitl SI7J /+) 6(Black Swiss)6(mixed C57Bl/66CBA) background whereas the study of CRKL transgenic6P190 transgenic was in a (C57Bl/66SJL)6(mixed C57Bl/ 66CBA) background. Similar unexpected results, using a dierent experimental approach, have recently been obtained for other proteins that have been strongly implicated in this type of leukemia. Dok1 is an adapter protein that is prominently tyrosine phosphorylated in primary CML patient material. However, leukemogenesis caused by a Bcr/Abl-expressing retrovirus was not abrogated in dokl 7/7 bone marrow, but was instead accelerated (Di Cristofano et al., 2001) . Although Stat5a/b was found to positively contribute to IL-7-induced Blineage precursor expansion, Bcr/Abl was still able to generate leukemias in null mutant bone marrow (Sexl et al., 2000) . A similar strategy was used to demonstrate that neither IL-3 nor GM-CSF are required for the induction of a CML-like myeloproliferative disease in mice (Li et al., 2001b) . Multiple studies had previously implicated IL-3 and Stat5 in the abnormal signals generated by Bcr/Abl.
Why does leukemia development still occur in the absence of Crkl in this mouse model? Bcr/Abl physically or functionally interacts with a wide range of other proteins (Voss et al., 2001) and aects a number of dierent pathways. Pathways such as those involving Ras may be activated through multiple mechanisms. Thus it is possible that the function(s) executed by Crkl in the leukemic process are taken over by other proteins downstream in the same pathway, or by redundant pathways that are providing compensation for the lack of Crkl in this genetic background. The nature of these modi®er(s) remains unknown. We have examined whether the expression levels of the small adapter Grb-2, which also plays a signi®cant role in the leukemogenic process caused by Bcr/Abl, (i.e., Li et al., 2001a; Kardinal et al., 2001 ) are altered. However, Grb-2 levels were comparable in several 129Sv inbred and outbred/mixed tissue samples (results not shown).
Others and we have previously examined the closely related Crk II in the context of Bcr/Abl-associated leukemogenesis. Although we detected tyrosine phosphorylation of Crk II in the leukemic spleen of a P190 transgenic, the amount was low as compared to Crkl (de Jong et al., 1995) . Voss et al. (2000) showed that the Tel ± Abl oncoprotein can directly tyrosine phosphorylate Crk II. However, Uemura et al. (1997) found that Crk was not tyrosine phosphorylated in Ba/F3 hematopoietic cells transfected by Bcr/Abl, whereas Crkl was. But to the best of our knowledge, to date there has been no analysis of Crk II in human patient material or in mouse models for Ph-positive leukemias.
Our data show that tyrosine phosphorylated Crk II protein is clearly present in P190 pre-B lymphoma cells with or without Crkl. However, neither the level of Crk II protein nor its tyrosine phosphorylation is prominently aected by the absence of Crkl. Therefore, the ablation of Crkl in P190 Bcr/Abl-caused leukemia did not result in a major quantitative shift towards the use of Crk II as an adapter. The detection of Crk II ± Bcr/Abl P190 complexes in crkl7/7 as well as +/+ lymphoma lysates clearly shows, for the ®rst time, that Crk II is involved in the leukemogenic process in vivo, and it is probable that modest levels of protein complex formation are sucient to transduce the Bcr/ Abl oncogenic signals and, over a prolonged period of time, cause leukemia. This is supported by the ®nding that there are no consistent dierences between the overall patterns of tyrosine phosphorylated proteins detected in P190 lymphomas expressing or lacking Crkl (not shown).
These results clearly have implications for the potential targeting of Crkl as a therapeutic in Phpositive leukemia. Although therapies that selectively target Crkl could bene®t from minimal toxicity, since ablation of Crkl appears to have no prominent eect on steady-state hematopoiesis (unpublished results), it is probable that maximum bene®t would only be obtained by simultaneously ablating Crk II function as well. It is therefore possible, that the therapeutic eect of cell-penetrating SH3 domain blocker peptides on the proliferation of CML blast cells could be attributed to the simultaneous ablation of Crkl and Crk II function.
Materials and methods
Mice
The generation of crkl7/7 mice was performed using previously described methods Kaartinen et al., 1995) . Brie¯y, segments of the mouse genomic crkl locus were cloned, a replacement vector was designed for positive-negative screening, and part of exon 1 of the crkl locus was replaced by the neomycin resistance gene in the R1 ES cell line. This cell line was derived from a cross between 129X1/SvJ6129S1/Sv-+ p + Tyr7c Kitl SI7J /+ mice. Chimeric mice were bred to 129X1/SvJ animals to obtain the null mutation in a`129Sv inbred' background. In this background, crkl null mutants die during embryogenesis because of defects found in heart, liver and placenta. The heart phenotype was very similar to that characterized in detail by Guris et al. (2001) , who also targeted the crkl locus (in the AK7 ES cell line) and obtained a null mutation in a 129S4/SvJaeSor6C57BI/6J background. Guris et al. (2001) described the crkl null phenotype in the context of phenocopying DiGeorge syndrome. The placental and hepatic phenotype of our crkl null mutant are not features of DiGeorge syndrome in human and will be described elsewhere (unpublished results).
In a mixed background (129X1/SvJ6129S1/Sv-+ p + Tyr7c Kitl SI7J /+6Black Swiss), crkl null mutants are viable and fertile. An analysis of seven litters with 55 pups showed an average birth weight of 1.19 g (n=13), 1.46 g (n=26) and 1.52 g (n=16) of 7/7, 7/+ and +/+ animals, respectively. The weight of the placentas was comparable among the genotypes. Animals with decreased birth weight had an increased chance of dying within the ®rst 4 days of life. Histological analysis of four such 7/7 pups (including lungs, heart, liver, kidneys, thymus and intestines) showed no obvious pathology. This is not unusual, since in general, mice with low birth weight, regardless of cause or genotype, have increased mortality.
Glucose tolerance tests on mice (three 7/7 and three +/ + females) at 6 months of age showed no pathological reactions in the null mutants. Surviving 7/7 animals reached the same weight and size as wild-type littermates by 6 months of age, were fertile and had normal litter sizes. No malignancies developed. FACS analysis of the major cell types showed normal pro®les of peripheral blood and bone marrow in newborns and adults. Null mutants appear to have a normal life span, and the 430 mice that were analysed older than 1.5 years showed no speci®c pathology with the exception of the following. Upon autopsy, some mice were found to have a small septum defect in the heart, an apparently very mild manifestation of the much more severe phenotype found in the inbred 129Sv background. One mouse had a normal and one very small kidney, whereas another animal apparently was born with a single kidney. These features are also occasionally observed in DiGeorge syndrome. At birth, around 53% of pups have bent or curved tails, with the tail vertebra showing an irregular, wedge-like shape. The lateral borders were fused to each other on one side, resulting in kinks. However, analysis of ossi®cation by staining for bone and cartilage using Alcian Blue and Alizarin Red at E18.5 revealed no abnormalities.
The BCR/ABL P190 transgenic mice lacking Crkl expression were generated using the crkl null mutants in the mixed background. The percentage of crkl null mutants transgenic for P190 was less than expected, due to perinatal death as mentioned above, but after weaning no excess mortality was observed.
The P190 BCR/ABL transgenic mouse strain has been previously described (Heisterkamp et al., 1990; Voncken et al., 1992a,b) . A line of P190 BCR/ABL mice established from founder 623 has been bred to obtain animals that contained the transgene on both chromosomes. Females of this line were mated to crkl 7/7 males and the ensuing P190 BCR/ ABL crkl+/7 mice were interbred to obtain genetically matched (7/7 and +/+) siblings. Crkl+/7 mice were not studied. Only F1 generation siblings post-weaning were included in the study. The survival curves were compared using the Log ± Rank test and dierences were not statistically signi®cant (P=0.27).
All animal studies were carried out at the Animal Care Facility of the Research Institute of Childrens Hospital Los Angeles in accordance with institutional guidelines. Animals were maintained in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
